Navigation Links
Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
Date:7/5/2012

HELSINKI, Finland, July 5, 2012 /PRNewswire/ --

Oncos Therapeutics, the biotech company executing a clinical development program on its next generation oncolytic viruses, today announced the appointment of its Clinical Advisory Board (CAB). Bringing together a group of recognized leading experts in Oncology and Oncolytic Virus drug development, combining a wealth of clinical, strategic, and scientific experience in cancer drug development, immunotherapy, and oncolytic viruses, the CAB is well suited to support the company's innovative development strategy.

"Oncolytic viruses have the potential to become an important next-generation modality of cancer therapeutics" says Kapil Dhingra, consultant to the company and member of the Clinical Advisory Board.

"I am very pleased to be able to work together with this distinguished group of experts. They are already making a significant and very valuable contribution to our strategy as well as brainstorming novel approaches, and being very pragmatic and feasibility-oriented", says Dr. Mikael von Euler, CMO and Head of Research at Oncos who was recently appointed as Chairman of the Clinical Advisory Board.

Dr. von Euler is pleased to include the following leading oncology experts into the CAB: Dr. Kapil Dhingra, former Head of Roche Global Oncology Clinical Development; Dr. Lee Helman, Head of Molecular Oncology Section at the National Cancer Institute (NCI) and Co-founder of the Sarcoma Alliance for Research Through Collaboration (SARC)  in the USA; Dr. Kevin Harrington of the Institute of Cancer Research (ICR) and the Royal Marsden Hospital in London, one of the most experienced European investigators in oncolytic virus trials; Dr. Eva Galanis of Mayo Clinic, a leading scientist in oncolytic viruses in the USA; Dr. Luca Gianni, Director of Medical Oncology at the San Raffaele Hospital in Milan and the 2011 ASCO recipient of the Gianni Bonadonna Breast Cancer Award for his achievements in advancing the field of breast cancer research and Dr. Elke Jäger of the Nordwest Krankenhaus in Frankfurt, a distinguished cancer immunotherapy opinion leader in Europe.

"Our CAB has already made a significant contribution to our clinical development strategy", comments Pekka Simula, CEO and Co-Founder of Oncos Therapeutics. "It's a thrilling experience for the entire Oncosteam to be executing the strategic ideas of such talented oncology experts."

About Oncos Therapeutics

Oncos Therapeutics, based in Helsinki, Finland, develops novel cancer therapies based on its next generation oncolytic viruses. Its ongoing clinical development program of the lead virus CGTG-102 is based on clinical experience from an experimental treatment program with ten different oncolytic viruses, and is planned to expand into several countries in the near future. For more information about Oncos visit http://www.oncos.com.


'/>"/>
SOURCE Oncos Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
2. OncoSec Medical Issues Letter to Shareholders
3. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
4. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
5. The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview
6. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
9. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
10. Sirnaomics Received NIH SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics
11. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , January 24, 2017 Analysis of the ... Liquid Biopsies - our new study reveals trends, R&D ... heading? If you are involved in this sector you must read ... potential revenues streams to 2027, assessing data, trends, opportunities and business ... Discover ...
(Date:1/24/2017)... 24, 2017 Sherpa Clinical Packaging ( ... services, is pleased to announce the appointment of Kevin ... the Sherpa team to lead Sherpa,s Operations group ... service excellence. Kevin is not new ... industries. He has extensive experience working for leading ...
(Date:1/24/2017)... India , January 24, 2017 According ... Regulators Market - Global Opportunity Analysis and Industry Forecast, ... at $4,456 million in 2015, and is expected to reach $7,065 ... to 2022. Asia-Pacific generated the highest revenue ... North America and Europe ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... Today, Taza Agua, ... award-winning bottles, designed specifically to optimize the drinking experience for K-Cup coffee, tea ... for introducing the world’s first untouched bottled water purposed exclusively for creating a ...
(Date:1/24/2017)... ... January 24, 2017 , ... TopConsumerReviews.com recently ... relieving premenstrual syndrome, or PMS . , Most women of child-bearing age ... include cramps, constipation, irritability, headaches, fatigue, and other discomfort. For some women, ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Choosing Wisdom-Solomon’s ... finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. , ... Judith Coats and Dr. David Coats. In September of 1983, they flew to ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Spiritual Vitamins: A Spiritual Energy ... God. “Spiritual Vitamins: A Spiritual Energy Booster” is the creation of published author, ... Yohannan’s new book engages the mind and spirit in a quest for fulfillment ...
(Date:1/24/2017)... ... January 24, 2017 , ... “The Octagon of Spiritual Balances”: a guide ... is the creation of published author, Pastor Bernard J. Weathers, pastor of Word of ... degree in religious education and a master degree in theology. , ““The Octagon of ...
Breaking Medicine News(10 mins):